Seeking Alpha

More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On...

More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On a regional basis, gains in the Western Hemisphere and Asia-Pacific Africa helped to offset a 3.4% decline of revenue in Europe. Sees full-year 2012 EPS of $5.05-$5.10, lower than prior guidance of $5.00-$5.07 and the consensus mark of analysts calling for $5.06. Shares +1.2% premarket. (PR)
Comments (4)
  • I think the guidance would be higher
    16 Oct 2012, 08:02 AM Reply Like
  • Nice increases considering we cannot get anything from Congress or President on direction. The fiscal cliff is coming, I'm surprised things are this good. VOTE
    16 Oct 2012, 08:07 AM Reply Like
  • Agreed. JNJ continues to deliver, even when analysts are rating them a sell. What a joke.
    16 Oct 2012, 08:12 AM Reply Like
  • Fwiw, M* still considers JNJ as "undervalued", pointing to a strong pipeline of new drugs more than offsetting weak performance in their consumer segment.
    16 Oct 2012, 08:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)